CELLECTA, INC. to Develop New Approach for Cancer Gene Discovery in Partnership with Roswell Park Cancer Institute and Health Research, Inc.
The goal of Cellecta's second project with RPCI is to develop, optimize, and perform high-throughput insertional mutagenesis screens to identify potential cancer drug targets.

'Personalized Medicine' Avances Colon Cancer Treatment Dr. Olga Falkowski on Testing for K-RAS Gene Mutation Helping Pinpoint Individual The
A new test for K-RAS gene mutation will help oncologist identify the medicines that will help most. That's the recent conclusion of both the American Society for Clinical Oncology and the National Comprehensive Cancer Network.

Texas Oncology Says "Be Smart, Know Your Genetic Risk" Genetic Testing Saves Lives
Take a simple blood test and learn if you have a gene that predisposes you to cancer and could take steps to save your life. More than 30,000 people in Texas are undiagnosed with BRCA-1 or BRCA-2 gene mutations and a greater risk for developing cancer, primarily breast or ovarian cancer. Texas Oncology's Hereditary Cancer Risk Assessment Program identifies patients who are at a higher risk of developing cancer because of an inherited mutated gene.